Skip to content
Catalyst

resveratrolFinding

Resveratrol has no detected effect on serum alkaline phosphatase

no difference foundStrong evidenceFinding

01 · The sentence it was drawn from

“As shown in Fig. 4 and Table 3, there were no significant differences between placebo and resveratrol group in the serum biomarkers including ALP (MD: 2.53, 95% CI: − 2.47, 7.52, p = 0.32, 9 studies, 523 participants), BAP (MD: 1.93, 95% CI: − 2.60, 6.47, p = 0.40, 2 studies, 90 participants), CTX (MD: -0.01, 95% CI: − 0.06, 0.03, p = 0.59, 3 studies, 218 participants), OCN (MD: -1.27, 95% CI: − 2.99, 0.46, p = 0.15, 3 studies, 218 participants), PINP (MD: -2.92, 95% CI: − 6.33, 0.50, p = 0.09, 2 studies, 90 participants), and PTH (MD: -0.86, 95% CI: − 1.75, 0.03, p = 0.06, 2 studies, 90 participants).”
Quoted verbatim from Effects of resveratrol supplementation on bone quality: a systematic review and meta-analysis of randomized controlled trials.
This finding among the 9 findings on its endpoint

resveratrol

Serum alkaline phosphatase

no difference found

Effect as reported

2.53mean difference

CI −2.47 to 7.52

Who
n = 523 · adults in 9 pooled RCTs (type 2 diabetes, NAFLD, obesity, healthy elderly and postmenopausal women), resveratrol 8 mg to 1500 mg daily against placebo, 4 weeks to 12 months; some trials with background medication in both arms
Dose studied
pooled doses 8 mg to 1500 mg daily, oral capsules or tablets

Strong evidencePMID 34420523 · 2021

02 · The study

Study
meta-analysis
Participants
523
Duration
not reported

Evidence, by strength

  • strongthis finding
  • moderate
  • limited
  • very limited
  • insufficient

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M6ZB47GY6BRP285AQ0FA2S3Q